Don't give up yet on biosimilars, Gottlieb says. Congress could give them a boost

While some drug pricing experts believe biosimilars won't deliver meaningful savings in the U.S.—and that it's time to throw in the towel—Scott Gottlieb thinks Congress could do a few things to boost the budding copycat field.